En Es
Categories

Industry News

AI Software Platform Aims to Synthesize Biomedical Knowledge

By HospiMedica International staff writers
12 Jun 2018

Image: The nference AI platform is designed to assist scientists’ abilities to generate holistic data-driven and unbiased hypotheses in a rapid manner (Photo courtesy of Shutterstock).nference (Cambridge , MA, USA), which focuses on artificial intelligence (AI)-powered life sciences, is developing an AI software platform to synthesize the exponentially growing biomedical knowledge.

The nference team, comprised of successful serial tech entrepreneurs and leading clinical, data and research scientists trained at Massachusetts Institute of Technology (MIT) and Harvard Medical School, works closely with pharmaceutical partners to solve the challenges in drug discovery and clinical research. This includes the identification of emerging targets and signaling pathways for disease processes with unmet need, stratification of patients in clinical trials, and prioritization of life-cycle opportunities for drugs in development. The nference AI platform plays a central role in augmenting the scientists’ abilities to generate holistic data-driven and unbiased hypotheses in a rapid manner.

nference uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the scientific, regulatory and commercial body of literature. The platform enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference is making biomedical knowledge computable, and building its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

“Natural language is the connective fabric across all therapeutic areas and support functions of large pharmaceutical companies,” said Venky Soundararajan, Ph.D., Founder and Chief Scientific Officer of nference and Qrativ. “Our AI platform leverages an ensemble of modern neural networks to decode the structure of literature. This kernel helps establish concordance between context-rich unstructured corpora and deep biological insights from structured databases spanning genomics to real world evidence. This presents a paradigm shift toward hypothesis-free scientific research and AI-augmented R&D decision-making.”

“The nference AI technology is enabling an important step forward in digitizing biology. nference’s approach reimagines big pharma R&D by enabling entirely novel hypotheses to emerge from the triangulation of insights across traditionally siloed structured databases and unstructured text documents,” said Diego Miralles, M.D., scientific advisor to nference and former Head of Johnson & Johnson Innovation. “This powerful platform establishes nference as a leader in the ongoing development of AI-powered drug discovery.”

“In addition to empowering drug discovery, the nference AI technology has the potential to transform both early and late-stage clinical development by allowing trialists and pharmaceutical companies to better guide patient selection and sooner anticipate side effects of novel therapies,” said Michael Gibson, M.D, scientific advisor to nference and Chief Executive Officer of the Baim Institute (Formerly Harvard Clinical Research Institute) and PERFUSE Research Institute at Harvard Medical School.

Related Links:
nference



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

08 Jan 2019
New AI Technology Pinpoints Negative Symptoms in Cancer Patients
Researchers from the University of Surrey and the University of California have developed a new artificial intelligence (AI) tool, which can predict symptoms and their severity throughout the course of a cancer patient's treatment.
Read More
08 Jan 2019
Luminex Acquires MilliporeSigma Flow Cytometry Portfolio
Luminex Corporation has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio.
Read More
31 Dec 2018
Deep Learning Technique Could Reveal Transparent Features in Medical Images
Engineers at the Massachusetts Institute of Technology have developed a deep learning technique that can reveal images of transparent features or objects that are nearly impossible to decipher in almost total darkness.
Read More
31 Dec 2018
Next-Gen Products Driving Global POC Molecular Diagnostics Market
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.
Read More
31 Dec 2018
Increased Breast Cancer Driving Global Digital Breast Tomosynthesis Market
The global digital breast tomosynthesis market is expected to grow at a CAGR of around 13% for the period 2019-2023, driven by the increasing incidence of breast cancer, growing popularity of digital breast tomosynthesis and consistent launch of new products.
Read More
31 Dec 2018
Global Urinalysis Market to Reach USD 1.5 Billion by 2024
The global urinalysis market is expected to grow at a steady CAGR of 5.40% over the 2016-2024 period to reach a value of USD 1.5 billion by the end of 2024, propelled mainly by the rising incidence of diabetes and urinal infections, globally.
Read More
31 Dec 2018
Bruker Completes Acquisition of Alicona Imaging
Bruker Corporation has completed its previously announced acquisition of Alicona Imaging GmbH, a provider of optical-based metrology products.
Read More
25 Dec 2018
New AI-Based Solutions Create Possibility for Early Cancer Screening
Two new Artificial Intelligence- (AI) based products released at this year’s Radiological Society of North America (RSNA) annual meeting in Chicago, USA, could create possibility for large-scale early cancer screening globally.
Read More
25 Dec 2018
Network-Based AI Engine Performs Airway Segmentation from CT Images
A new 2.5D convolutional neural network (CNN)-based artificial intelligence (AI) engine enables accurate airway segmentation from computed tomography (CT) images without any human interaction.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions